← SynDRA
NCS-382
SynDRA canonical compound SYN0462596 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | GABBR2 |
|---|
| Mechanism of action | GABA receptor antagonist |
|---|
| Indication | epilepsy |
|---|
| Disease area | Neurology |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CAMK2A
- GMNN
- HDAC6
- PIN1
- VDR
Cross-references
Synonyms
- Tocris-0780
- BDBM50246039
- NCGC00024786-01
- PD132480
- E73741
- BDBM50246038
- 2-(5-hydroxy-5,7,8,9-tetrahydrobenzo[7]annulen-6-ylidene)acetic acid
- HMS3266D12
- SCHEMBL16909353
- KBio2_004529
- KBio2_001961
- Spectrum_001481
- GLXC-21973
- KBioSS_001961
- SpecPlus_000674
- KBio1_001714
- VVA50501
- KBio2_007097
- orb1704305
- DivK1c_006770
- NCS-382, Sodium Salt
- SMR001230736
- SCHEMBL29389498
- BRD-A85025557-001-02-5
- EX-A14300
- MFCD11046018
- BRD-A67433117-001-01-8
- AKOS025294298
- NCS-382sodium
- MLS002153323
- NCS-382 sodium
- NCS-382 sodium monohydrate
- SR-01000597695-1
- HY-W008645
- UNII-8WW2CD9KK4
- AKOS024458646
- DA-76040
- BPBio1_000947
Look up NCS-382 in the interactive SynDRA portal →